Navigation Links
CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company's proprietary synDNA(TM) technology at the 2007 DNA Vaccines conference to be held in Malaga, Spain between May 23 and May 25.

Dr. Chen comments, "We have successfully conducted tests of synDNA(TM) based vaccines in mice, rabbits and non-human primates. The data to be presented will demonstrate the stimulation of the immune response comparing synDNA(TM) based vaccines to traditional plasmid DNA vaccines designed for the prevention of seasonal flu, HIV, smallpox and Hepatitis B. The tests indicate that the immune response triggered by synDNA(TM) vaccines is comparable to, and in some cases more effective than responses mediated by plasmid DNA. Data will also be shown demonstrating the effectiveness of a novel vaccine that protects against a highly virulent form of avian (bird) flu in animal challenge studies. These challenge experiments demonstrated that synDNA(TM) is just as effective as plasmid in mediating a protective immune response when the host is attacked by virulent viruses.

Malcolm Skolnick, CEO, states, "DNA vaccines have proven to be a potent means of providing protective immunity against viruses, bacteria and parasites in many species from fish to primates. Our animal tests demonstrate that DNA vaccines made with synDNA(TM) technology are not only effective in eliciting robust immune responses, but also provide protection against dangerous pathogens. Presentation of our data at the DNA vaccine conference is a great opportunity to showcase and discuss our work with other experts in this field including major pharmaceutical and biotech companies."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on
'"/>




Page: 1 2

Related medicine technology :

1. CytoGenix Announces Successful Testing of synDNA Vaccine for Avian Influenza Virus
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 Dr...lts for prostate-specific antigen (PSA) recurrence...nts of biochemical recurrence rate in a Phase III ... for injection) or monthly leuprolide in prostate .... Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)..., , NEW YORK, Dec. 3 Guid...rm, today announced the launch of their Sleep Apne...t monitors and projects trends and market share in...p Apnea Tracker captures actual patient usage for ...nited States from 15 different equipment providers...
(Date:12/3/2009)..., , SUNNYVALE, Calif., Dec. 3 /PRNewswire-..., a biopharmaceutical company focused on developin...ugs for the treatment of immune mediated diseases ...bcast and conference call on, Tuesday, December 8,...e and 8:00am Pacific Time) to discuss clinical dat...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 1Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 3ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 1ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
...AS, April 4, 2008 Data from five studies sponsore...d at the National Kidney,Foundation (NKF) 2008 Spr...e utilization studies involve PROCRIT(R) (Epoetin ...g utilization patterns and,costs of PROCRIT (EPO) ...s,related to chronic kidney disease (CKD) patients...
...iously-Stated Guidance Remains Unchanged, PRINCET...EDX ) today issued the following statement in resp... discontinuing its Phase 3 clinical,trial of front...LA-4,antibody (tremelimumab) compared to chemother...ey M. Nichol, M.B.Ch.B., Senior Vice President, Pr...
Other Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effort b...et Programs Are Lost in Final Health Care Reform ... The New England Journal of Medicine today pub...th care reform, co-authored by Irwin Redlener, M.D... National Center for Disaster Preparedness and Pro...
(Date:12/4/2009)...with knowledge of risks, many hesitate to take bre... Dec. 4 (HealthDay News) -- Worries about side eff...ican women at high risk for breast cancer are will...ase, a new study finds. , In an effort to infor... researchers at the University of Michigan Compreh...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ..., ON LOVE ,, Kathryn Budig, a prominent yoga te...e to healing--with a viewing of Twilight,s New Moo...nal.com: ,, http://www.elephantjournal.com/200...ournal.com: TASHI KING AND BREAST CANCER ,, el...
(Date:12/4/2009)... , JEFFERSON CITY, Mo., Dec. 4 /PRNewswire/ ...ctor Paul Crosetti, State Fire Marshal Randy Cole,...en,s fire safety program sponsored by Farmers call... safety day at the Missouri Capitol December 9. .../20080605/LATH062 ) ,, "The call for fire safet...
(Date:12/4/2009)...le who have had an ischemic stroke are at higher l... of medication can reduce that risk. One of the si...s, otherwise known as blood thinners, of which the...tudy to determine whether the use of antithromboti...r a seven-year period found that in each of the ye...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
..., Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP...igational new,drug (IND) application to the U.S. F...und is an internally developed, orally-bioavailabl...r,patients in early 2008., "This IND submission i...
... N.Y., Dec. 3 Big A Drug Stores, Inc. has,selecte...al estate,solutions, to exclusively manage the dis...California. Big A Drug Stores, Inc. is a chain of ...gs,","Drug Fair," and "Drug Barn" (2 stores)., "W...
...APOLIS Although more and more drug advertisements...oximately $21 billion dollars that pharmaceutical ...is targeted to physicians, doctors in training (re...c. published in the December issue of the journal ...
...and PITTSBURGH, Dec. 2 Forest,Laboratories, Inc. ...ed that,Mylan has received an approvable letter fr...response to its New Drug Application (NDA) for,neb...icated that a recent inspection of,a backup manufa...
... communication with doctors and respect for role o...Y, Dec. 2 (HealthDay News) -- The death of a child...dparents, siblings, friends, even the child,s doct...ymptoms and stress of life-threatening illness -- ...
...ESTER, Ill. Hospital staff nurses who work extend...at work, or obtain less sleep are more likely to e... study published in the December 1 issue of the jo...ed from 895 full-time hospital staff nurses, who c...
Other Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn 2Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 3Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4
HOME MULTI-DRUG TEST
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
Medicine Products: